Shanghai Fosun Pharmaceutical (02196) plans to repurchase H shares not exceeding HKD 1 billion.

Shanghai Fosun Pharmaceutical (02196) announced that, based on confidence in the group's development prospects and recognition of its intrinsic value, it will repurchase H shares of the company under a general authorization granted to the board of directors at the company's annual general meeting on June 16, 2026, as well as at the H-share and A-share meetings. With the board's approval, the company plans to repurchase H shares within 12 months starting from August 27, 2026, with a total fund not exceeding HKD 1 billion. The company will determine the use of the repurchased H shares based on the H share repurchase authorization and market conditions, including but not limited to canceling the repurchased H shares or holding them as treasury shares. The board of directors is confident in the group's business development and prospects, and believes that the current H share price is below its actual value. Therefore, the board believes that implementing the share repurchase plan is in the best interests of the company and its shareholders as a whole.